A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study

@article{Proietto2010ACT,
  title={A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study},
  author={J. Proietto and Aila M. Rissanen and Joyce B. Harp and Ngozi Erondu and Qiping Yu and Shailaja Suryawanshi and Michael E. Jones and Amy O. Johnson-Levonas and Steven B. Heymsfield and Keith L. Kaufman and John M. Amatruda},
  journal={International Journal of Obesity},
  year={2010},
  volume={34},
  pages={1243-1254}
}
Objective:To evaluate the weight loss efficacy, safety and tolerability of taranabant, a CB1R inverse agonist, in obese and overweight patients.Design:Multicenter, double-blind, randomized, placebo-controlled study.Subjects:Patients ⩾18 years old, BMI 27–43 kg m−2, were randomized to placebo (n=209) or taranabant 0.5 mg (n=207), 1 mg (n=208) or 2 mg given orally once daily (n=417) for 52 weeks.Measurements:Key efficacy measurements included body weight (BW), waist circumference (WC), lipid… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIOEurope Study

LF Van Gaal, AJ Scheen, +3 authors O. Ziegler
  • Eur Heart J
  • 2008

Medical Mangement of Obesity

GA Bray
  • Handbook of Obesity: Clinical Applications. Informa Healthcare:
  • 2008

Taranbant plasma concentrations are increased when co-administered with ketoconazole or ditiazem

C Addy, J Cote, +3 authors H Li
  • Obesity, Program Abstract Supplement
  • 2007

Similar Papers

Loading similar papers…